<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M537</article-id>
      <article-id pub-id-type="publisher-id">molbank-2007-M537</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>2-[5-chloro(bromo)-3-hydrazono-2-oxo-2,3-dihydro-1<italic>H</italic>-indolin-1-yl]acetohydrazide</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rachid</surname>
			<given-names>Bouhfid</given-names>            
          </name>
		  <xref rid="af1-molbank-2007-M537" ref-type="aff">1</xref>
		</contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joly</surname>
			<given-names>Nicolas</given-names>
		  </name>
		  <xref rid="af2-molbank-2007-M537" ref-type="aff">2</xref>
		</contrib>
		<contrib contrib-type="author">
          <name>
            <surname>Lequart</surname>
			<given-names>Vincent</given-names>
		  </name>
		  <xref rid="af2-molbank-2007-M537" ref-type="aff">2</xref>
		</contrib>
		<contrib contrib-type="author">
          <name>
            <surname>Martin</surname>
			<given-names>Patrick</given-names>
		  </name>
		  <xref rid="af2-molbank-2007-M537" ref-type="aff">2</xref>
		</contrib>
		<contrib contrib-type="author">
          <name>
            <surname>Massoui</surname>
			<given-names>Mohammad</given-names>
		  </name>
		  <xref rid="af1-molbank-2007-M537" ref-type="aff">1</xref>
		</contrib>
		<contrib contrib-type="author">
          <name>
            <surname>Essassi</surname>
			<given-names>El Mokhtar</given-names>
		  </name>
		  <xref rid="af1-molbank-2007-M537" ref-type="aff">1</xref>
		  <xref rid="c1-molbank-2007-M537" ref-type="corresp">*</xref>
		</contrib>
      </contrib-group>
      <aff id="af1-molbank-2007-M537"><label>1</label>Laboratoire de Chimie Organique H&#xE9;t&#xE9;rocyclique, P&#xF4;le de comp&#xE9;tences Pharmacochimie Universit&#xE9; Mohammed V-Agdal, BP: 1014 Avenue Ibn Batouta, Rabat, Morocco</aff>
      <aff id="af2-molbank-2007-M537"><label>2</label>Blood-Brain Barrier Laboratory (EA 2465), IUT of B&#xE9;thune, University of Artois, BP 819, F-62408 B&#xE9;thune</aff>
      <author-notes>
        <corresp id="c1-molbank-2007-M537"><label>*</label> Author to whom correspondence should be addressed. E-mail: <underline><email>emessassi@yahoo.fr</email></underline></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>05</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>05</month>
        <year>2007</year>
      </pub-date>
      <volume>2007</volume>
      <issue>2</issue>
      <elocation-id>M537</elocation-id>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>11</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>12</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2007 by MDPI (http://www.mdpi.org/).</copyright-statement>
        <copyright-year>2007</copyright-year>
        <license>
          <p>Reproduction is permitted for noncommercial purposes.</p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>isatin</kwd>
		<kwd>hydrazone</kwd>
		<kwd>indoline</kwd>
		<kwd>acetohydrazide</kwd>		
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <p>Isatin derivatives exhibit significant biological, medicinal and pharmacological activities, [<xref ref-type="bibr" rid="B1-molbank-2007-M537">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2007-M537">2</xref>] such as antituberculous, antihypoxing agent, anticonvulsant, antihyperglycemic; active against <italic>salmonella</italic>, <italic>typhi</italic> and against <italic>vibrio cholerae</italic>. Besides, they are used in treating and preventing pestvirus. [<xref ref-type="bibr" rid="B3-molbank-2007-M537">3</xref>] We describe in this work, the synthesis of new indoline derivatives.</p>
	  <p><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M537-i001.tif"/></p>
      <p>To a solution of <bold>1a-b</bold> (3.7 mmol) in 10 mL of ethanol, was added hydrazine hydrate (7.4 mmol). The mixture was refluxed for 6 h. After cooling the precipate was filtered and recrystallised from ethanol to afford product <bold>2a-b</bold>.</p>
      <p><bold><italic>2-[5-chloro-3-hydrazono-2-oxo-2,3-dihydro-1H-indolin-1-yl]acetohydrazide 2a:</italic></bold> Yield: (74%). Melting Point: &gt; 250&#xB0;C. MS (IE): M<sup>+</sup>(m/z) = 267 (76%)/ 269 (25%); 180 (100%). &#x3C5; (cm<sup>-1</sup>): 3310, 3285, 3113, 3091, 1675, 1654, 1598, 1532. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 3.52 (s, 2H, NH<sub>2</sub>), 4.12 (s, 2H, NH<sub>2</sub>); 4.61 (s, 2H, NCH<sub>2</sub>); 7.00-7.40 (m, 3H, H<sub>Ar</sub>); 9.27 (s, 1H, NH). <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): 41.2 (NCH<sub>2</sub>); 111.2, 117.6, 126.9 (CH<sub>Ar</sub>); 117.8, 124.6, 138.4 (Cq); 159.1 (C=O<sub>amide</sub>); 161.4 (C=N<sub>imine)</sub>; 165.3 (C=O<sub>hydrazide</sub>). Elemental analysis: Calculated for C<sub>10</sub>H<sub>10</sub>ClN<sub>5</sub>O<sub>2</sub>: C, 44.87%; H, 3.77%; N, 26.16%; Found: C, 44.62%; H, 3.88%; N, 25.96%.</p>
	  <p><bold><italic>2-[5-bromo-3-hydrazono-2-oxo-2,3-dihydro-1H-indolin-1-yl]acetohydrazide 2b:</italic></bold> Yield: (70%). Melting Point: &gt; 250&#xB0;C. MS(IE): M<sup>+</sup>(m/z) = 311 (39%)/ 313 (37%); 224 (100%). &#x3C5; (cm<sup>-1</sup>): 3320, 3279, 3162, 3089, 1687, 1656, 1599, 1533. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 3.34 (s, 2H, NH<sub>2</sub>), 4.06 (s, 2H, NH<sub>2</sub>); 4.57 (s, 2H, NCH<sub>2</sub>); 6.91-7.51 (m, 3H, H<sub>Ar</sub>); 9.32 (s, 1H, NH). <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>): 40.6 (NCH<sub>2</sub>); 111.4, 120.4, 129.6 (CH<sub>Ar</sub>); 115.0, 124.6, 138.7 (Cq); 159.0 (C=O<sub>amide</sub>); 161.2 (C=N<sub>imine)</sub>; 167.2 (C=O<sub>hydrazide</sub>). Elemental analysis: Calculated for C<sub>10</sub>H<sub>10</sub>BrN<sub>5</sub>O<sub>2</sub>: C, 38.48%; H, 3.23%; N, 22.44%; Found: C, 38.31%; H, 3.35%; N, 22.56%.</p>
  </body>
  <back>
    <app-group>
       <app id="app1-molbank-2007-M537">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2007-M537-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M537-s001-mod.mol">
        <label>Supplementary File 1</label>
        </supplementary-material>
		<supplementary-material id="molbank-2007-M537-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M537-s001.mol">
        <label>Supplementary File 2</label>
        </supplementary-material>
		<supplementary-material id="molbank-2007-M537-s003" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M537-s002-mod.mol">
        <label>Supplementary File 3</label>
        </supplementary-material>
		<supplementary-material id="molbank-2007-M537-s004" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2007-M537-s002.mol">
        <label>Supplementary File 4</label>
        </supplementary-material>
	  </app>
    </app-group>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2007-M537">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pandeya</surname>
              <given-names>S.N.</given-names>
            </name>
            <name>
              <surname>Sriram</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <source>Acta Pharm. Turc.</source>
          <year>1998</year>
          <volume>40</volume>
          <fpage>33</fpage>
        </citation>
      </ref>
      <ref id="B2-molbank-2007-M537">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarangapani</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Narayan</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Jayamma</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <source>Indian Drugs</source>
          <year>1998</year>
          <volume>35</volume>
          <fpage>336</fpage>
        </citation>
      </ref>
      <ref id="B3-molbank-2007-M537">
        <label>3.</label>
        <citation citation-type="patent">
          <person-group person-group-type="author">
            <name>
              <surname>Pevear</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Nitz</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Seipel</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>PCT Int. Appl.</article-title>
          <patent>WO98 36,752</patent>
		  <comment>(Cl.A61K3 1/555)27 Aug 1998, US Appl. 12 Feb. 1997, 803, 675</comment>
        </citation>
      </ref>
      <ref id="B4-molbank-2007-M537">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joshi</surname>
              <given-names>K.C.</given-names>
            </name>
            <name>
              <surname>Jam</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Chand</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <source>J. Indian Chem. Soc.</source>
          <year>1983</year>
          <volume>LX</volume>
          <fpage>760</fpage>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>